A recent study showed targeting DDR1 as a therapeutic strategy against resistance to BRAF and MEK inhibitors (81), further confirming the significance of our findings, which suggest an unprecedented role of the interactome of DDR1, BCR, and ABL1 proteins with EGFR-ERBB2-4 signaling in tumor progression. This evidence concerns the gene MAP2K7 and neoplasm.